VMTHF (Venus Medtech (Hangzhou)) Marketable Securities: $14.97 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VMTHF Venus Medtech (Hangzhou) Inc VMTHF
52 GF Score
Price $0.42
GF Value $1.27
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) Marketable Securities?

Venus Medtech (Hangzhou) VMTHF 52 Marketable Securities is $14.97 Mil as of Dec. 2025. GuruFocus rates VMTHF with a GF Score™ of 52/100 and a GF Value™ of $1.27. The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Venus Medtech (Hangzhou)'s Marketable Securities for the quarter that ended in Dec. 2025 was $14.97 Mil.

Venus Medtech (Hangzhou)'s annual Marketable Securities increased from Dec. 2023 ($1.01 Mil) to Dec. 2024 ($1.05 Mil) and increased from Dec. 2024 ($1.05 Mil) to Dec. 2025 ($14.97 Mil).

Venus Medtech (Hangzhou)  (OTCPK:VMTHF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Venus Medtech (Hangzhou) Marketable Securities Related Terms

Venus Medtech (Hangzhou) Marketable Securities Historical Data

* Premium members only.

The historical data trend for Venus Medtech (Hangzhou)'s Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Medtech (Hangzhou) Marketable Securities Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 1.01 1.05 14.97

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.00 1.05 1.99 14.97
VMTHF
52GF Score
Venus Medtech (Hangzhou) Inc VMTHF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Medtech (Hangzhou) Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $14.97 Mil mean?
Venus Medtech (Hangzhou) (VMTHF) has a Marketable Securities of $14.97 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Venus Medtech (Hangzhou) and its competitors.
Is Venus Medtech (Hangzhou)'s Marketable Securities too high?
Venus Medtech (Hangzhou)'s current Marketable Securities is $14.97 Mil. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Marketable Securities compare to ABT and SYK?
Venus Medtech (Hangzhou)'s Marketable Securities of $14.97 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Marketable Securities is $14.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Marketable Securities of $14.97 Mil. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Marketable Securities is $14.97 Mil. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Marketable Securities is $14.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.

Key valuation signals for VMTHF:

  • Marketable Securities: $14.97 Mil
  • GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Medtech (Hangzhou) Business Description

Other Exchanges 02500:Hong Kong
Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for VMTHF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$1.27
GF Value